The 16th World ADC London Summit highlighted advances in bispecific, dual payload, and biparatopic ADCs addressing tumor heterogeneity and resistance with novel payloads and ADC architectures, but clinical efficacy results were not reported.
As ADCs continue to mature into established oncology modalities, the field faces a new set of scientific and translational challenges. Clinical saturation around established payload classes, emerging resistance mechanisms, and unmet medical needs are placing renewed emphasis on payload innovation, molecular design, and smarter clinical positioning to continue to deliver patient impact. Returning in February 2026, the 16th World ADC London Summit convenes the global ADC community to address these challenges head-on, bringing together more than 110 speakers from Europe, North America, and Asia to explore how next-generation ADCs can be optimized for durability, tolerability, and earlier-line use. Spanning 4 days of scientific programming, seminars, and workshops, the meeting offers five parallel tracks covering discovery, preclinical and translational development, clinical lessons, process and analytical development, and manufacturing and supply chain.
none listed (Wed,) reported a other. The 16th World ADC London Summit highlighted advances in bispecific, dual payload, and biparatopic ADCs addressing tumor heterogeneity and resistance with novel payloads and ADC architectures, but clinical efficacy results were not reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: